A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Sponsor

David Bushnell (Other)

Overall Status

Recruiting

CT.gov ID

NCT06148636

Collaborator

Holden Comprehensive Cancer Center (Other), National Cancer Institute (NCI) (NIH), Perspective Therapeutics (Industry)

Enrollment

Location

Arms

48.3

Anticipated Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.

Condition or Disease	Intervention/Treatment	Phase
Neuroendocrine Tumors Neuroendocrine Tumor of the Lung Neuroendocrine Tumor Grade 1 Neuroendocrine Tumor Grade 2 Neuroendocrine Tumor of Pancreas	Drug: [212Pb] VMT-α-NET Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT	Early Phase 1

Detailed Description

This research study is designed to explore if a new radiotherapeutic (radioactive) drug, named 212Pb (212-lead) VMT-α-NET, works against neuroendocrine tumor cells. To begin researching this drug, we need to determine if [212Pb] VMT-α-NET is safe and tolerable when used as a cancer treatment. As a safety study, it is unknown if the treatment is safe or effective.

The study will also estimate the radiation dose to the kidneys for this treatment. To calculate this radiation dose, imaging is also performed with the sister drug, [203Pb] VMT-α-NET using SPECT/CT imaging. Each participant is assigned a radiation dose to the kidneys that cannot be exceeded. The study is testing the safety of the specific radiation dose to the kidneys when using [212Pb] VMT-α-NET.

Participants are assigned a radiation dose based on how other participants have tolerated the [212Pb] VMT-α-NET. The amount of [212Pb] VMT-α-NET administered varies person-to-person because of each person's unique tumor uptake of [203Pb] VMT-α-NET and how long it lasts in the body.

The study involves 2 treatments, about 8 to 10 weeks apart. The drug is given by infusion once per treatment. The participants also receive an infusion of amino acids to help protect the kidneys as well as medications to help protect against nausea (feeling sick to the stomach).

Once a participant is administered the [212Pb] VMT-α-NET, they must be followed (i.e. come back to the clinic) for at least 6 months for safety assessments. Safety assessments include blood tests to check bone marrow, kidney, and liver function as well as urinary tests to check kidney function. Participants will also have imaging at 6 months post-treatment to measure how their tumors responded to therapy.

Participants will have lifelong follow-up for this study.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

24 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

3 + 3 dose escalation3 + 3 dose escalation

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine Tumors

Actual Study Start Date :

Nov 10, 2023

Anticipated Primary Completion Date :

Nov 20, 2026

Anticipated Study Completion Date :

Nov 20, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: -1 Dose Level This dose level is used if the starting dose level is deemed to have unacceptable toxicity. Participants are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 200 cGy.	Drug: [212Pb] VMT-α-NET Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage. Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
Experimental: Cohort 1 This is the starting dose level for participants. Participants are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 350 cGy.	Drug: [212Pb] VMT-α-NET Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage. Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
Experimental: Cohort 2 If the participants from Cohort 1 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 600 cGy.	Drug: [212Pb] VMT-α-NET Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage. Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
Experimental: Cohort 3 If the participants from Cohort 2 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 810 cGy.	Drug: [212Pb] VMT-α-NET Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage. Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
Experimental: Cohort 4 If the participants from Cohort 3 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 1050 cGy.	Drug: [212Pb] VMT-α-NET Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage. Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.

Outcome Measures

Primary Outcome Measures

Determine recommended therapeutic dose of [212Pb] VMT-α-NET [From study day 1 through 6 months post-treatment]
Determine the recommended phase 2 dose for therapy with [212Pb]VMT-Α-NET administered intravenously to patients with neuroendocrine tumors that have progressed despite therapy.

Secondary Outcome Measures

Objective Response Rate (ORR) [At 6 months post-treatment]
Determine objective response rate using the standardized technique (RECISTv1.1) in patients with treatment refractory neuroendocrine tumors (NETs) when treated with [212Pb] VMT-α-NET. Objective response rate is the incidence of complete response and partial response added together.
Maximum tolerated radiation dose for kidneys [From study day 1 through 12 months post treatment]
Determine the maximum tolerated critical organ dose limit for kidneys for therapy with [212Pb]VMT-α-NET administered intravenously to patients with neuroendocrine tumors that have progressed despite therapy. Maximum tolerated radiation dose is indicated by the number and severity of renal (i.e. kidney) toxicities observed through 12 months post-treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Ability to understand and willingness to provide informed consent
Stated willingness to comply with all study procedures and availability for duration of study
Aged ≥ 18 years to 80 years at the time of study drug administration
Pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be a well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2)
Disease not amenable to curative intent treatment (e.g., surgery) and in addition, has shown either clinical or radiographic progression on all available therapies known to confer clinical benefit in the opinion of the referring physician. If a patient is suspected of experiencing a clinical non-response to current treatment (i.e., the patients clinical symptomatology has not improved despite treatment) the patient may be included if confirmed by the study investigator.
Prior peptide receptor radionuclide therapy (PRRT)
Positive somatostatin receptor (SSTR) PET/CT utilizing an FDA approved agent within 12 months prior to anticipated day 1 of treatment demonstrating SSTR positive tumor sites.
≥1 evaluable site of disease measuring ≥ 1.0 cm in diameter on CT or MRI as measured per RECIST
Adequate performance status (ECOG of 0 or 1; or KPS of ≥70).
No other active malignancy that requires immediate treatment. Slow growing concurrent cancers (such as prostate cancer) are acceptable with appropriate documentation from their treating oncologists for that primary.
Not experiencing an uncontrolled intercurrent illness such as: infection requiring inpatient admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations, or any other condition that would limit compliance with study requirements as determined by study team members.
Agreement to adhere to Lifestyle Considerations throughout study duration:

During this study, participants are asked to:

Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice, [pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices] from the day prior to therapy through 5 days post-treatment.
Comply with their antihypertensive medications, if prescribed.
Refrain from excessive alcohol use.
Refrain from "natural" or "herbal" supplements unless approved by the treating physician and research team.
Utilize contraception for at least 6 months in uterine-bearing patients and at least 3 months in testes-bearing patients.

Exclusion Criteria:

Platelets < 100,000 k/mm3
Absolute neutrophil count (ANC) of < 1500 cells/mm3
Total bilirubin ≥ 2.5x institutional upper limit of normal for age and weight
Aspartate aminotransferase (AST) > 2.5 x the institutional upper limit of normal
Alanine aminotransferase (ALT)> 2.5 x the institutional upper limit of normal
eGFR < 50 mL/min/1.73 m2 (using the Cockcroft Gault formula)
Proteinuria grade 2 (i.e., ≥ 3+ proteinuria)
Individuals who are pregnant or breast feeding. A pregnancy test will be administered to individuals of child-bearing potential (per institutional policies) at screening. Participants must agree to pregnancy tests prior to each administration of a radionuclidic agent for this study.
Individuals of reproductive potential who decline to use effective contraception through the study. Contraception should only be stopped after a conversation with the attending oncologist.
Lactating individuals who decline to withhold breastfeeding their child. Participants may not breast feed during this study and should only resume after the study in consultation with their oncologist.
Patient with increased fall risk in the opinion of healthcare professionals
Therapy (including radiation therapy) within 2 calendar weeks of the start of study therapy. (Toxicities from prior therapies should have resolved to ≤ CTCAE grade 1 or a new baseline established).
Therapeutic investigational drug within 4 weeks of C1D1 (imaging agents are acceptable)
History of congestive heart failure and cardiac ejection fraction ≤ 40%
Patients for whom, in the opinion of their physician, a 24-hour discontinuation of somatostatin analogue therapy represents a health risk.
Long-acting somatostatin analogue treatment ≤ 14 days of C1D1
Prior external beam radiation dose of >16 Gy to the kidneys.
Prior external beam radiation (including brachytherapy) involving 25% of the bone marrow (excluding scatter doses of ≤ 5 Gy) as estimated by a radiation oncologist.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTA-tyr3-Octreotide, Octreoscan®, or 68Ga-Octreotide.